The FDA’s authorisation enables qualified laboratories to address testing demands while providing significant economic advantage, LGC says
LGC’s SARS-CoV-2 real-time and end-point RT-PCR Test has been granted emergency use authorisation (EUA) by the FDA. It’s capable of processing up to 35,000 tests per day.
The FDA’s authorisation enables qualified laboratories to address testing demands while providing significant economic advantage, LGC says.
Mark Dearden, MD, LGC, Biosearch Technologies, said: “This tool is a game-changer in our fight against COVID-19. It offers the gold standard of PCR testing but with economics to support routine diagnostics at scale.”
Dearden continued: “The benefits of large-scale PCR testing can’t be underestimated. We know that extensive and frequent testing is a key tool for tracking and managing the spread of the virus. Used in concert with other point-of-need testing and continued vaccine rollout, the LGC solution can enhance our ability to fight the pandemic.”
The system is designed to be flexible and scalable, allowing organisations to meet evolving needs.
The company has been involved in the response to the COVID-19 pandemic since January 2020. It has a track record supporting the scientific and healthcare community with diagnostics for public health diseases as well as public health emergencies such as influenza, H1N1 (swine flu), Zika, and Ebola.